Shares of Hims & Hers are moving higher after President-elect Donald Trump nominated Dr. Marty Makary, a pancreatic surgeon at Johns Hopkins University, as commissioner of the Food and Drug Administration. Makary is also Chief Medical Officer at startup startup Sesame, which prescribes compounded GLP-1 weight loss drugs through the mail. Hims & Hers also sells compounded weight loss drugs. The stock in midday trading is up 18%, or $4.60, to $29.93.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- HIMS Stock Surges after Court Case with Eli Lilly Gets Put on Hold
- Hims & Hers Health Expands Board with New Appointment
- FDA tirzepatide status report ‘moderately positive’ for Hims & Hers, says Citi
- Hims & Hers jumps as status report says patients unable to obtain branded GLP-1s
- Hims & Hers announces daily meal replacement bars and shakes